Grail Archives - Page 3 of 3 - Medical Design Sourcing

Grail, Quest Diagnostics to collaborate on Galleri multi-cancer early detection blood test

Grail announced that it entered into an agreement with Quest Diagnostics (NYSE:DGX) to collaborate on Grail’s Galleri multi-cancer blood test.

Quest Diagnostics is slated to provide phlebotomy services in support of the Galleri multi-cancer early detection blood test, according to a news release.

Menlo Park, Calif.-based Grail completed enrollment for the Pathfinder prospective study of Galleri in clinical practice in December 2020. The 6,600-participant, multi-site, international study under an FDA investigational device exemption application has already completed its second planned independent data and safety monitoring board review and will have initial results, plus additional clinical validation data from a separate study, available in the first half of this year.

The company announced just last month that, following completed enrollment, it expects to introduce Galleri in the second quarter of this year. The blood test will be prescription on…

Grail to debut multi-cancer blood test in Q2

Grail announced today that it expects to introduce its Galleri multi-cancer early detection blood test in the second quarter of 2021.

Menlo Park, Calif.-based Grail completed enrollment for the Pathfinder prospective study of Galleri in clinical practice just last month, according to a news release.

The 6,600-participant, multi-site, international study under an FDA investigational device exemption application has already completed its second planned independent data and safety monitoring board review and will have initial results, plus additional clinical validation data from a separate study, available in the first half of this year.

In combining the results from the Pathfinder trial with the foundational circulating cell-free genome atlas study, Grail expects the data to support Galleri’s introduction as a laboratory-developed test.

An earlier version of Galleri previously demonstrated the ability to detect more than 50 types of cancers (…

Illumina may buy back Grail

Illumina (NSDQ:ILMN) may acquire Grail for more than $8 billion — four years after it spun out the cancer detection startup.

That’s according to a Bloomberg report out yesterday, which cited people familiar with the matter.

Analysts told Bloomberg that the acquisition would put Illumina — a giant in the DNA sequencing space — in direct competition with its customers. But the potential of Grail’s early cancer detection tech may be too good for Illumina to pass up.

Grail has been preparing for an IPO on the Nasdaq, where it would trade under the symbol GRAL. It plans to commercially launch its Galleri early cancer detection test next year.